Table 4.
Treatment-related adverse events (for adverse events ≥ Grade 3)
| Event | Anlotinib + TQB2450 (N = 34) |
||
|---|---|---|---|
| All Grades, n (%) | Grades 1–2, n (%) | Grade ≥3, n (%) | |
| Alanine aminotransferase increased | 18 (52.9) | 17 (50.0) | 1 (2.9) |
| Hand-foot syndrome | 18 (52.9) | 15 (44.1) | 3 (8.8) |
| Hypertension | 18 (52.9) | 13 (38.2) | 5 (14.7) |
| Aspartate aminotransferase increased | 17 (50.0) | 16 (47.1) | 1 (2.9) |
| Hypertriglyceridemia | 16 (47.1) | 14 (41.2) | 2 (5.9) |
| Hypercholesterolemia | 15 (44.1) | 14 (41.2) | 1 (2.9) |
| Diarrhea | 14 (41.2) | 11 (32.4) | 3 (8.8) |
| Prolonged QTc | 13 (38.2) | 7 (20.6) | 6 (17.6) |
| White blood cell count decreased | 12 (35.3) | 11 (32.4) | 1 (2.9) |
| Neutrophil count decreased | 10 (29.4) | 9 (26.5) | 1 (2.9) |
| Low-density lipoprotein increased | 9 (26.5) | 8 (23.5) | 1 (2.9) |
| Mucositis oral | 6 (17.6) | 5 (14.7) | 1 (2.9) |
| Loss of appetite | 6 (17.6) | 5 (14.7) | 1 (2.9) |
| Weight loss | 5 (14.7) | 4 (11.8) | 1 (2.9) |
| Abdominal pain | 5 (14.7) | 4 (11.8) | 1 (2.9) |
| Blood bilirubin increased | 5 (14.7) | 4 (11.8) | 1 (2.9) |
AEs were summarized with descriptive statistics.